Tests a device that detects melanoma cells circulating in the blood
Tests a non-invasive device that counts melanoma cells in blood in adults.
Key facts
- Who runs it
- Cytoastra
- Where
- Madison, United StatesSee the site
- Trial code
- Registry title
- In Vivo Liquid Biopsy of Melanoma (Cytophone)
- Status
- Recruiting
- People taking part
- 180 people, planned
- Started
- 11 Feb 2025
- Planned end
- 31 Mar 2026
- Type of study
- Interventional
- Treatments tested
- Cytophone
- Record updated
- 11 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a confirmed melanoma diagnosis to test the Cytophone, a non-invasive device that counts melanoma cells in the blood.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Melanoma confirmed by tissue examination (histology). No stage is named in the record.
Main reasons for not taking part
- Cannot give informed consent
- Serious heart, liver, brain, hormone or other major body disease that makes the study difficult or risky
- Ongoing serious or severe infection
- Pregnant or breast-feeding, or planning pregnancy during the study
- History of severe constipation
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Histological documented diagnosis of melanoma
- Participants having provided informed consent with signature on informed consent form: the informed consent process should be complete with full discussion of all requirements and possible risks
- Must be able to sit for up to 60 minutes
Who cannot take part
- Unable to provide informed consent to participate in the study, such as a mental condition rendering the participant unable to understand the nature, scope, and possible consequences of the study
- Clinically relevant cardiovascular, hepatic, neurological (e.g., evidence of organic brain syndrome), endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the participant at risk by participating in the study
- Persistent significant or severe infection, either acute or chronic
- Any known history of severe preexisting constipation
- Pregnant or breast-feeding women or those who plan to become pregnant during the study
- Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- SSM Health Dean Medical Group Specialty ServicesMadison, United StatesContact: Lisa Lepeak, MDTaking people
About the trial
What the trial wants to find out
The Cytophone is a first in the world patented system to identify and count single circulating melanoma cells in blood circulation inside the human body. The Cytophone has a unique capability to find rare melanoma cells in the blood by an assessment of 100-500 times greater amounts of blood volume than routine blood tests. The important benefit of the Cytophone diagnosis is that the test does not require injection or any skin incision (i.e., non-invasiveness). The goal of this clinical trial is to demonstrate evidence of the capability of the Cytophone test to indicate a risk of metastasis and define CTC counts that correlate with melanoma recurrence, progression of metastatic disease, and therapy efficacy. The investigators believe that clinical trials will provide evidence that the Cytophone can diagnose risk of melanoma metastasis and recurrence earlier than existing methods.
The group in the trial
- Cytophone applicationTreatment being tested
It is anticipated that Cytophone diagnostic procedure will start with 30-min preparation including ultrasound imaging of an examined vessel, photo of a skin area above the vessel and quick navigation of the PAFC probe on the vessel using near-infrared viewer. After completion, the Cytophone monitoring will be conducted for 30-60 min and will include noninvasive irradiation of the vessel by a laser beam(s) using a safe for human laser energy level.
Treatment: Cytophone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- In Vivo Liquid Biopsy for Early Detection of Metastatic Melanoma
- Plain-language title
- Tests a device that detects melanoma cells circulating in the bloodGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06488365, who can take part
- Record updated
- 11 March 2025